How to Read Cancer Trial Results: Survival Terms Explained

After a major cancer meeting, such as the European Society for Medical Oncology (ESMO) Congress held Oct. 23 to 27, 2026, in Madrid, news about new trial results arrives quickly. Headlines mention median survival, hazard ratios and progression-free survival. These terms can be confusing, but understanding them can help you judge whether a result applies to you and how big the benefit really is.

Here is a plain-language guide to the words you will see most often.

What the Trial Phases Mean

According to the National Cancer Institute (NCI), cancer treatments are tested in phases:

• Phase 1 trials check whether a treatment is safe and find the right dose. They usually include about 15 to 30 people.
• Phase 2 trials look at whether the treatment seems to work, for example by shrinking tumors. They usually include about 50 to 100 people.
• Phase 3 trials compare a new treatment with the current standard treatment in 100 to several thousand people. Results from phase 3 trials help the Food and Drug Administration (FDA) decide whether to approve a treatment.

In phase 3 trials, people are usually randomized, meaning a computer assigns them to a group by chance. NCI notes that this helps prevent bias, so differences between groups are more likely due to the treatment itself.

Overall Survival

Overall survival measures how long people live after starting treatment, from any cause. It is the most direct measure of whether a treatment helps people live longer. Because it takes time to measure, early reports may say overall survival data are "immature," meaning not enough time has passed to know.

Progression-Free Survival and Similar Terms

Progression-free survival is how long people live without their cancer growing or spreading. It is often measured before overall survival is known. Related terms include:

• Disease-free or event-free survival: used after surgery or other treatment meant to cure, it measures how long people stay free of the cancer coming back or other defined events.
• Response rate: the share of people whose tumors shrank by a set amount. A complete response means no cancer can be seen on scans.
• Duration of response: how long tumor shrinkage lasts.

A treatment can improve progression-free survival without clearly helping people live longer, so it is worth asking which measure a headline describes.

What "Median" Means

The median is the middle point. If a trial reports a median survival of 19 months, half of the patients lived longer than 19 months and half lived less. It is not a prediction for any one person. Many people live well beyond the median. Some reports also give "landmark" figures, such as the percentage of patients alive at two or three years, which can be easier to compare.

What a Hazard Ratio Tells You

A hazard ratio compares how often an event, such as cancer growth or death, happens in one group vs. another over time. A hazard ratio of 1 means no difference. A hazard ratio below 1 favors the new treatment. For example, a hazard ratio of 0.68 for death is often described as a "32% lower risk of death."

That percentage is a relative difference. It does not tell you how many people actually benefited. Absolute numbers, such as 70% vs. 62% alive at three years, give a clearer picture of the real-world difference.

"Statistically Significant" and Other Fine Print

• Statistically significant: the difference was large enough that it is unlikely to be due to chance. A result that is "not statistically significant" may still look better on paper, but researchers cannot be confident it is real.
• Interim analysis: a planned early look at the data. Results can change with more follow-up.
• Noninferiority: some trials test whether a new approach, such as a gentler schedule, is "not worse" than the standard rather than better.
• Presented vs. published: results shared at a meeting have not always been reviewed by outside experts and published in a medical journal. Published results include more detail.

References

1. "How Do Clinical Trials Work?" National Cancer Institute. Updated Nov. 8, 2024.
2. "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry." U.S. Food and Drug Administration. December 2018.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.